文献速递浆细胞疾病

接受艾基奥仑赛或标准方案治疗的三类暴露复发难治多发性骨髓瘤患者的健康相关生活质量:3期随机开放标签KarMMa-3临床试验的患者报告结局

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
PubMed 文献 · Lancet Haematol · 2024-01-01

KarMMa-3试验中386例三类暴露复发难治多发性骨髓瘤患者随机接受艾基奥仑赛(n=254)或标准方案(n=132),分析患者报告结局。艾基奥仑赛组在多数主要PRO领域较基线改善且优于标准方案组,至临床意义改善时间更短,但QLQ-MY20疾病症状、治疗副作用和EQ-5D-5L指数评分未超过组内最小重要差异阈值。

要点

  • 艾基奥仑赛组在多数主要PRO领域较基线有统计学显著且临床意义的改善
  • QLQ-MY20疾病症状、治疗副作用和EQ-5D-5L指数评分未超过组内最小重要差异阈值
  • 艾基奥仑赛组在多数QLQ-C30和QLQ-MY20领域及EQ-5D-VAS至临床意义改善时间短于标准方案组

核心结论

  • 对于既往接受过治疗的三类暴露复发难治多发性骨髓瘤患者,艾基奥仑赛较标准方案提供更好的健康相关生活质量。
  • PRO数据突显了艾基奥仑赛一次性输注相较于标准方案持续治疗在生活质量上的延长获益。

研究设计与样本

  • 随机、开放标签、3期KarMMa-3试验(NCT03651128),386例患者随机分配至艾基奥仑赛组(n=254)或标准方案组(n=132)。
  • 纳入标准:≥18岁、可测量疾病、ECOG体能状态评分0或1、既往接受过2至4线方案(包括免疫调节剂、蛋白酶体抑制剂和达雷妥尤单抗)、末次治疗后记录疾病进展。
  • 标准方案组包括:达雷妥尤单抗+泊马度胺+地塞米松;达雷妥尤单抗+硼替佐米+地塞米松;伊沙佐米+来那度胺+地塞米松;卡非佐米+地塞米松;或埃罗妥珠单抗+泊马度胺+地塞米松。
  • 患者预期在基线和随访时间点完成EORTC QLQ-C30、QLQ-MY20、EQ-5D和EQ-5D视觉模拟量表(数据截止2022年4月18日)。
  • PRO包括九个预设主要领域:EORTC QLQ-C30总体健康状况-生活质量、躯体功能、认知功能、疲乏和疼痛;QLQ-MY20疾病症状和治疗副作用;五水平EQ-5D(EQ-5D-5L)指数评分和EQ-5D视觉模拟量表。

主要发现

  • 患者随机分配时间为2019年5月6日至2022年4月8日;中位年龄63岁(IQR 55-68);151例(39%)女性;250例(65%)白人,36例(9%)黑人或非裔美国人,19例(5%)西班牙裔或拉丁裔,12例(3%)亚洲人,7例(2%)其他种族。
  • 中位随访18.6个月(IQR 14.0-26.4),PRO依从性全程高于75%。
  • 总体最小二乘均值较基线变化有利于艾基奥仑赛组,多数领域Hedges' g效应量为0.3至0.7。
  • 艾基奥仑赛组在主要PRO兴趣领域显示统计学显著且临床意义的改善,但QLQ-MY20疾病症状、治疗副作用和EQ-5D-5L指数评分在各评估访视显示改善但未超过组内最小重要差异阈值。
  • 艾基奥仑赛组至临床意义改善时间短于标准方案组:QLQ-C30领域除角色功能、腹泻和经济困难外;QLQ-MY20领域除体像外;以及EQ-5D-VAS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor T-cell therapy idecabtagene vicleucel (ide-cel) showed significantly improved progression-free survival compared with standard regimens in adults with relapsed and refractory multiple myeloma who had received two to four previous regimens in the ongoing phase 3 KarMMa-3 trial (NCT03651128). This study analysed patient-reported outcomes (PROs), a KarMMa-3 secondary endpoint. METHODS: In the randomised, open-label, phase 3 KarMMa-3 trial, 386 patients in hospitals (≥18 years of age, with measurable disease and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who had received two to four previous regimens-including an immunomodulatory agent, a proteasome inhibitor, and daratumumab-and had documented disease progression after receiving their last dose of the last therapy) were randomly assigned to ide-cel (n=254) or standard regimens (daratumumab, pomalidomide, and dexamethasone; daratumumab, bortezomib, and dexamethasone; ixazomib, lenalidomide, and dexamethasone; carfilzomib and dexamethasone; or elotuzumab, pomalidomide, and dexamethasone; n=132). Patients were expected to complete the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life C30 Questionnaire (QLQ-C30), Multiple Myeloma Module (QLQ-MY20), EQ 5 dimensions (EQ-5D), and EQ-5D visual analogue scale (VAS) at baseline and follow-up timepoints (data cutoff April 18, 2022). PROs included nine prespecified primary domains: EORTC QLQ-C30 GHS-quality of life (QoL), physical functioning, cognitive functioning, fatigue, and pain; QLQ-MY20 disease symptoms and side effects of treatment; and five-level EQ-5D (EQ-5D-5L) index score and EQ-5D visual VAS. Differences in overall least-squares mean changes from baseline to month 20 were analysed using post-hoc constrained longitudinal data analysis. Time to confirmed improvement or deterioration from baseline was analysed using Cox proportional hazard models. FINDINGS: Patients were randomly assigned between May 6, 2019, and April 8, 2022. Overall, the median age was 63 years (IQR 55-68); 151 (39%) patients were female; and 250 (65%) patients were White, 36 (9%) Black or African American, 19 (5%) Hispanic or Latino, 12 (3%) Asian, and seven (2%) of other race. The median follow-up was 18·6 months (IQR 14·0-26·4). PRO compliance was higher than 75% throughout. Overall least-squares mean changes from baseline favoured ide-cel with Hedges' g effect sizes from 0·3 to 0·7 for most domains. Patients in the ide-cel group showed statistically significant and clinically meaningful improvements across the primary PRO domains of interest, with the exception of QLQ-MY20 disease symptoms, side effects of treatment, and EQ-5D-5L index score, which showed improvement across assessment visits but did not exceed the within-group minimally important difference thresholds. The ide-cel group had shorter times to clinically meaningful improvement than the standard regimens group in QLQ-C30 domains except in role functioning, diarrhoea, and financial difficulties; in QLQ-MY20 domains except body image; and in EQ-5D-VAS. INTERPRETATION: Ide-cel offers improved health-related quality of life compared with standard regimens for patients with relapsed and refractory multiple myeloma after previous lines of therapy. The PRO data highlight the extended QoL benefits of a one-time infusion with ide-cel compared with continuous treatment with standard regimens in the treatment of triple-class exposed patients with relapsed and refractory multiple myeloma. FUNDING: 2seventy bio and Celgene, a Bristol Myers Squibb Company.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Delforge M, Patel K, Eliason L, et al. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024. PMID: 38423700. doi:10.1016/S2352-3026(24)00005-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。